1. Pink Sheet
  2. >>Legal & IP

Patent Day At The Supreme Court: A Split Decision On Split Decisions?

 
• By Brenda Sandburg

US justices appear divided on whether Patent Trial and Appeal Board can issue a final decision on only some of patent claims challenged. Justice Sotomayor said petitioner is trying to get around the court's Cuozzo decision, but others cited ambiguity in the statute and efficiency of tackling all claims.

US Supreme Court building with 2nd statue on right

The second of the two patent cases the Supreme Court heard on Nov. 27 played out in front of a much smaller audience, but it was no less lively a performance by the justices and lawyers. The petitioner challenging the scope of inter partes review (IPR) decisions seemed to be facing a losing battle when questioned by Supreme Court justices Sonia Sotomayor and Elena Kagan. But other justices pointed to the ambiguity of the statute and the goal of the proceeding, suggesting the court may reach a split decision. 

The case, SAS Institute Inc. v

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

Trump Administration Push For Dismissal, Transfer Of Mifepristone Case Leaves Overhang For Pharma

 
• By Sarah Karlin-Smith

The Trump Administration requested a dismissal or transfer of a lawsuit seeking to tighten the safety requirements for the abortion pill mifepristone on procedural grounds, which still leaves the administration's position on the case's merits unclear.

Viatris Agrees To $335m Opioid Settlement Ending US State, Local Government Cases

 
• By Dean Rudge

Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.

How States And Courts Could Insulate America From An Anti-Vaccine Executive Branch

 
• By Sarah Karlin-Smith

The mood at the World Vaccines Congress in Washington, D.C. was bleak given Robert F. Kennedy Jr.’s rise to lead the Trump Administration’s Health and Human Services Department, but vaccine lawyers offered an optimistic outlook and ideas for countering his vaccine agenda.

Lilly Targets Sale Of Repackaged, Redosed Zepbound, Mounjaro In Lawsuit

 
• By Cathy Kelly

Eli Lilly is seeking an injunction barring a weight loss clinic from dispensing modified versions of its GLP-1 products.

More from Pink Sheet

Sponsors Like START Rare Disease Pilot, Will Prasad Maintain Its Momentum?

 
• By Kate Rawson

Sponsors reported faster development times for products that joined the pilot program intended to speed rare disease treatments in CBER.

EU HTA Regulation: ‘Stepping Beyond’ JCAs May Be Needed For Very Rare Disease Drugs

 
• By Francesca Bruce

Cooperation between health technology assessment bodies across the EU will lead to a better joint clinical assessment process over time, but patients cannot afford a lengthy wait for improvements, speakers at a cell & gene therapy conference said.

EU Pharma Reform: Exclusivity Vouchers Alone Are Insufficient Incentive For Antimicrobials, Industry Says

 
• By Eliza Slawther

European pharma trade associations EFPIA and EUCOPE outline their respective views on how the EU’s pharma legislation overhaul should tackle antimicrobial resistance, and why transferable exclusivity vouchers alone will not suffice as incentives.